Literature DB >> 25659240

The association between thromboembolic complications and blood group in patients with atrial fibrillation.

Jodi M Blustin1, Robert D McBane1, Matylda Mazur1, Naser Ammash1, Ondrej Sochor2, Diane E Grill3, Waldemar E Wysokinski4.   

Abstract

OBJECTIVE: To determine whether blood type affects the risk of thromboembolic complications in patients with atrial fibrillation (AF). PATIENTS AND METHODS: The Mayo Clinic electronic medical record was searched (between January 1, 2004, and December 31, 2010) to identify all patients with AF with blood group assessment. Records were analyzed for stroke, transient ischemic attack, left atrium appendage thrombus, cerebral or peripheral embolism, and hemorrhagic stroke. All events were adjusted for Congestive heart failure, Hypertension, Age >75 Years, Diabetes mellitus, and Stroke/transient ischemic attack score.
RESULTS: Of the 47,816 patients with AF, 14,462 had blood group type available (40% women; mean age, 73±12 years). These included 12,363 patients with nonvalvular atrial fibrillation (NVAF) (40% women; mean age, 73±12 years) and 2099 patients with valvular AF (41% women, mean age, 73±12 years). Within patients with NVAF, the rate of peripheral embolization was significantly lower in those with blood type O (2.0%) than in those with other blood types (3.0%; odds ratio, 0.66; 95% CI, 0.52-0.84; P<.001). Neither cerebral thromboembolic (8.1% for "O" vs 8.2% for "non-O" blood group for NVAF and 7.29% vs 7.76% for valvular AF) nor cerebral hemorrhage (2.0% each group) events rates differed by blood group.
CONCLUSION: Blood group O may be protective against peripheral cardioembolic complications of NVAF, which may relate, in part, to reduced circulating von Willebrand factor levels. Cerebral thromboembolic event rates did not differ by blood group.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25659240     DOI: 10.1016/j.mayocp.2014.11.013

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

Review 1.  Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact.

Authors:  Polychronis E Dilaveris; Harold L Kennedy
Journal:  Clin Cardiol       Date:  2017-03-08       Impact factor: 2.882

2.  Blood type association with bleeding outcomes at delivery in a large multi-center study.

Authors:  Najeebah A Bade; Jamil M Kazma; Richard L Amdur; Julia Ellis-Kahana; Homa K Ahmadzia
Journal:  J Thromb Thrombolysis       Date:  2020-08       Impact factor: 2.300

3.  Von Willebrand Factor and ADAMTS13 as Predictors of Adverse Outcomes in Patients With Nonvalvular Atrial Fibrillation.

Authors:  Waldemar E Wysokinski; Rowlens M Melduni; Naser M Ammash; Danielle T Vlazny; Ewa Konik; Rayya A Saadiq; Izabela Gosk-Bierska; Joshua Slusser; Diane Grill; Robert D McBane
Journal:  CJC Open       Date:  2020-11-13

4.  Evaluation of blood type as a potential risk factor for early postpartum hemorrhage.

Authors:  Mais Ali-Saleh; Ofer Lavie; Yoram Abramov
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

Review 5.  Silent Atrial Fibrillation: Definition, Clarification, and Unanswered Issues.

Authors:  Harold L Kennedy
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-10-08       Impact factor: 1.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.